Abbott Laboratories

Abbott scores very high on predictability. Its products address basic health needs (baby nutrition, chronic disease care, diagnostics) with steady demand cycles.

The business isn’t tied to boom-bust tech trends or volatile commodities; even after removing one-time COVID test spikes, Abbott’s core sales grew robustly (health products sales rose 9–10% in 2023–24 excluding pandemic tests)).

The revenue mix is well-balanced: when COVID diagnostics plunged, diabetes monitors and nutrition sales picked up the slack. Patient populations (infants, diabetics, heart patients) provide recurring revenue. This is effectively a “toll booth” model in healthcare – demand persists regardless of economic conditions.

Federal/insurance reimbursement can tighten, but demographics (aging population, rising diabetes prevalence) are secular tailwinds. Jurisdiction risks are low – Abbott is U.S.-based with diversified global sales (62% international), giving stability against any single market. Management guidance has been conservative and generally met or exceeded.

We see Abbott’s cash flows and earnings as highly predictable, giving it an 80+ score here. (Minor unpredictability arises from litigation uncertainty in nutrition, but that has had limited financial impact so far.) Overall, Abbott’s growth is steady and largely in line with long-term healthcare trends.